Markets

Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations

Oct 19, 2026 · 02:53 AM ET· updated 1h ago

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line data for olomorasib, an

Why It Matters

Lilly is showing new test results for several cancer medicines at a big medical conference. These updates help doctors and investors see how well the drugs work against competitors.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LLY1,256.85

+5.24 (+0.42%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.